skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
11665675
Filing Dt:
02/19/2009
Publication #:
Pub Dt:
06/18/2009
Inventors:
Jonathan D. Roth, Christen M. Anderson, Alain D. Baron
Title:
Methods for treating obesity and obesity related diseases and disorders
Assignment: 1
Reel/Frame:
020838/0240Recorded: 04/22/2008Pages: 5
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
04/16/2008
Exec Dt:
04/16/2008
Exec Dt:
04/21/2008
Assignee:
9360 TOWNE CENTRE DRIVE
SAN DIEGO, CALIFORNIA 92121
Correspondent:
DEBRA VILLANUEVA
9360 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
Assignment: 2
Reel/Frame:
029198/0345Recorded: 10/25/2012Pages: 5
Conveyance:
CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
08/08/2012
Assignee:
9360 TOWNE CENTRE DRIVE
ATTN: INTELLECTUAL PROPERTY GROUP
SAN DIEGO, CALIFORNIA 92121
Correspondent:
AMYLIN PHARMACEUTICALS, LLC
9360 TOWNE CENTRE DRIVE
ATTN: INTELLECTUAL PROPERTY GROUP
SAN DIEGO, CA 92121
Assignment: 3
Reel/Frame:
029195/0555Recorded: 10/26/2012Pages: 70
Conveyance:
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP
Assignor:
Exec Dt:
09/19/2012
Assignee:
1800 CONCORD PIKE
WILMINGTON, DELAWARE 19803
Correspondent:
AMYLIN PHARMACEUTICALS, LLC
9360 TOWNE CENTRE DRIVE
ATTN: INTELLECTUAL PROPERTY GROUP
SAN DIEGO, CA 92121

Search Results as of: 05/21/2024 06:33 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT